This circuit is primed by heterogeneous glioblastoma neo-antigens (like EGFRvIII) and subsequently eliminates target cells using tandem CARs that recognize homogenous but nonspecific antigens in glioblastoma (like EphA2 and IL13Rα2). The gene discussed is EPHA2; the disease is glioblastoma.